<DOC>
	<DOCNO>NCT01143740</DOCNO>
	<brief_summary>This open-label study evaluate efficacy , safety tolerability RO5045337 patient liposarcoma eligible debulking surgery . Prior surgery , patient receive 2-3 cycle RO5045337 , orally 10 day follow 18 day rest per cycle . Anticipated time study treatment 3 month . Patients incomplete resection may treat additional 3 cycle RO5045337 .</brief_summary>
	<brief_title>A Study RO5045337 Patients With Liposarcomas Prior Debulking Surgery</brief_title>
	<detailed_description />
	<mesh_term>Liposarcoma</mesh_term>
	<criteria>adult patient , &gt; /=18 year age well differentiate and/or dedifferentiate liposarcoma eligible tumor debulking surgery willing undergo tumor biopsy , treatment ECOG performance status 01 previous chemotherapy and/or radiation liposarcoma ; previous debulking surgery acceptable patient receive agent therapy treat malignancy patient require anticoagulant therapy and/or antiplatelet therapy preexist gastrointestinal disorder may interfere absorption drug history seizure disorder unstable CNS metastasis clinically significant cardiovascular disease history long QT syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>